government rolls out a pilot program in July covering GLP-1s for weight loss for people enrolled in Medicare, which covers Americans age 65 or older and people with disabilities.
According to NICE guideline NG28 , GLP-1 receptor agonists like Ozempic may be considered for adults with type 2 diabetes who have specific criteria, including a BMI of 35 kg/m or higher (adjusted for ethnicity) and specific problems associated with high weight, or a BMI lower than 35 kg/m where insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities
Malozowski S (2023)
Its very much like were building the plane while flying it. In fact, some of those newer benefits werent even included in their models because the data came out after their analysis was complete
That commercial relationship is disclosed throughout, and the buyer's framework in section 14 is built to evaluate any microinfusion kit in the category, not only ours
For those tracking their dose escalation week by week, this concentration simplifies the entire process